(2S,4S)-1-(tert-butoxycarbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid

We are (2S,4S)-1-(tert-butoxycarbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid CAS:1378388-16-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  (2S,4S)-1-(tert-butoxycarbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid
CAS.NO:   1378388-16-9
Synonyms:
I(2S,4S)-4-(Methoxymethyl)-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester
(2S,4S)-1-(Tert butoxy carbonyl)-4-(methoxy methyl)pyrrolidine-2-carboxylic acid
(2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid
(2S, 4S) -4- (methoxymethyl) pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
(2S,4S)-4-(Methoxymethyl)-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester

Molecular Formula:  C12H21NO5
Molecular Weight: 259.29900

Physical and Chemical Properties:
Density: 1.2±0.1 g/cm3
Boiling point: 371.2±27.0 °C at 760 mmHg
Melting point: /
Flash point: 178.3±23.7 °C
Refractive index:1.485

Specification:
Appearance:  White  powder
Purity:≥99.0%
Loss on drying:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
Intermediates of Velpatasvir CAS:1377049-84-7.

Related News: For example, an active ingredient to relieve pain is included in a painkiller.(1R,2S)-1-Amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide 4-methylbenzenesulfonate The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.Diethyl acetamidomalonate CAS:1068-90-2 The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.2605-14-3 The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.